Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Editorial & Opinion

Treatment Strategy for Rifampin-Susceptible Tuberculosis. Reply.

  • Authors : Paton NI; National University of Singapore, Singapore, Singapore .; Cousins C

Subjects: Rifampin*/Rifampin*/Rifampin*/pharmacology ; Rifampin*/Rifampin*/Rifampin*/therapeutic use ; Tuberculosis*/Tuberculosis*/Tuberculosis*/drug therapy

  • Source: The New England journal of medicine [N Engl J Med] 2023 Jun 15; Vol. 388 (24), pp. 2298.Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print Cited Medium: Internet ISSN:

Record details

×
Editorial & Opinion

Treatment Strategy for Rifampin-Susceptible Tuberculosis.

  • Authors : Burman W; Public Health Institute at Denver Health, Denver, CO .; Fox GJ

Subjects: Rifampin*/Rifampin*/Rifampin*/therapeutic use ; Tuberculosis*/Tuberculosis*/Tuberculosis*/drug therapy; Humans

  • Source: The New England journal of medicine [N Engl J Med] 2023 Jun 15; Vol. 388 (24), pp. 2296-2297.Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print Cited Medium: Internet ISSN:

Record details

×
Editorial & Opinion

Treatment Strategy for Rifampin-Susceptible Tuberculosis.

  • Authors : Leung CC; Hong Kong Tuberculosis, Chest, and Heart Diseases Association, Hong Kong, China .; Migliori GB

Subjects: Rifampin*/Rifampin*/Rifampin*/therapeutic use ; Tuberculosis*/Tuberculosis*/Tuberculosis*/drug therapy; Humans

  • Source: The New England journal of medicine [N Engl J Med] 2023 Jun 15; Vol. 388 (24), pp. 2297-2298.Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print Cited Medium: Internet ISSN:

Record details

×
Editorial & Opinion

Treatment Strategy for Rifampin-Susceptible Tuberculosis.

  • Authors : Boeree MJ; Radboud University Medical Center, Nijmegen, the Netherlands .; Heinrich N

Subjects: Rifampin*/Rifampin*/Rifampin*/therapeutic use ; Tuberculosis*/Tuberculosis*/Tuberculosis*/drug therapy; Humans

  • Source: The New England journal of medicine [N Engl J Med] 2023 Jun 15; Vol. 388 (24), pp. 2297.Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Single-Dose Rifapentine in Household Contacts of Patients with Leprosy.

  • Authors : Wang L; From the Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, and the National Center for Leprosy Control, Chinese Center for Disease Control and Prevention (CDC) (L.W., Hongsheng Wang, L.Y., M.Y., H.J., Y.S., W.Z., J.S., X. Yang, H.G., G.Z., B.W.), Key Laboratory of Basic and Translational Research on Immune-Mediated Skin Diseases, Chinese Academy of Medical Sciences, and Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and Sexually Transmitted Infections (Hongsheng Wang), the Department of Epidemiology and Health Statistics, School of Public Health, Southeast University (X. Yu), and the Department of Epidemiology, School of Public Health, Nanjing Medical University (C.S.), Nanjing, Yunnan Provincial CDC, Kunming (J.Y., L.X., J.H., T.S.), Guizhou Provincial CDC, Guiyang (Jinlan Li, J. Liu, D.W., Y.W.), Hunan Provincial CDC, Changsha (Junhua Li, Y.K., B.L., H.C.), Sichuan Provincial People's Hospital, Chengdu (Y.N., Hao Wang, Y. Liu, X.S.), WenShan Prefecture Institute of Dermatology, Wenshan (H.L.), and Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (B.W.) - all in China.; Wang H

Subjects: Leprosy*/Leprosy*/Leprosy*/epidemiology ; Leprosy*/Leprosy*/Leprosy*/prevention & control ; Leprosy*/Leprosy*/Leprosy*/transmission

  • Source: The New England journal of medicine [N Engl J Med] 2023 May 18; Vol. 388 (20), pp. 1843-1852.Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print Cited Medium: Internet ISSN:

Record details

×
Editorial & Opinion

A Shorter Regimen for Rifampin-Resistant Tuberculosis. Reply.

  • Authors : Nunn AJ; Medical Research Council Clinical Trials Unit at University College London, London, United Kingdom .; Phillips PPJ

Subjects: Rifampin* ; Tuberculosis*; Humans

  • Source: The New England journal of medicine [N Engl J Med] 2019 Sep 12; Vol. 381 (11), pp. e22.Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print Cited Medium: Internet ISSN:

Record details

×
Editorial & Opinion

A Shorter Regimen for Rifampin-Resistant Tuberculosis.

  • Authors : McCaw ZR; Harvard T.H. Chan School of Public Health, Boston, MA.; Meng Z

Subjects: Rifampin* ; Tuberculosis*; Humans

  • Source: The New England journal of medicine [N Engl J Med] 2019 Sep 12; Vol. 381 (11), pp. e22.Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print Cited Medium: Internet ISSN:

Record details

×
Editorial & Opinion

A Shorter Regimen for Rifampin-Resistant Tuberculosis.

Subjects: Rifampin* ; Tuberculosis*; Humans

  • Source: The New England journal of medicine [N Engl J Med] 2019 Sep 12; Vol. 381 (11), pp. e22.Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print Cited Medium: Internet ISSN:

Record details

×
Editorial & Opinion

A Short Regimen for Rifampin-Resistant Tuberculosis.

  • Authors : Churchyard GJ; From the Aurum Institute, Parktown, and the School of Public Health, University of Witwatersrand, Johannesburg - both in South Africa.

Subjects: Rifampin* ; Tuberculosis*; Humans

  • Source: The New England journal of medicine [N Engl J Med] 2019 Mar 28; Vol. 380 (13), pp. 1279-1280. Date of Electronic Publication: 2019 Mar 13.Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print-Electronic Cited Medium:

Record details

×
Editorial & Opinion

Four-Month Rifapentine Regimens for Tuberculosis. Reply.

Subjects: Rifampin*/Rifampin*/Rifampin*/analogs & derivatives ; Rifampin*/Rifampin*/Rifampin*/therapeutic use ; Tuberculosis*/Tuberculosis*/Tuberculosis*/drug therapy

  • Source: The New England journal of medicine [N Engl J Med] 2022 Mar 17; Vol. 386 (11), pp. 1095-1096.Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print Cited Medium: Internet ISSN:

Record details

×
  • 1-10 of  408 results for ""Rifampin""